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Anatomy of a discovery: M1 and M2
macrophages
Charles Dudley Mills *
Biomedical Consultants, Marine on St. Croix, MN, USA
M1 and M2 macrophage-type responses kill or repair in vivo. The unique ability of
macrophages to make these polar opposite type of responses provides primary host
protection and maintains tissue homeostasis throughout the animal kingdom. In humans
and other higher animals, M1 and M2-type macrophage responses also initiate and
direct T cells/adaptive immunity to provide additional protection such as Th1 (cytotoxic)
or Th2 (antibody-mediated) type responses. Hence, macrophages were renamed M1
and M2 to indicate the central role of macrophages/innate immunity in immune systems.
These findings indicate that the long held notion that adaptive immunity controls innate
immunity was backward: a sea change in understanding how immune responses occur.
The clinical impact of M1/kill and M2/repair responses is immense playing pivotal roles
in curing (or causing) many diseases including infections, cancer, autoimmunity, and
atherosclerosis. How M1/M2 came to be is an interesting story that, like life, involved
Direction, Determination, Discouragement, and Discovery.
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Introduction
A revolution in immunology is underway. Macrophages and innate immunity are now known to
be the primary host defense in all animals (1). It had long been thought that adaptive responses
(T and B cells) direct innate immunity (2–6). Immunology had it backward. Why? I am reminded
of the humorous phrase: “If you hear the sound of hooves, don’t look for zebras.” That is, look
for the obvious (Figure 1). Immunology overlooked animal anatomies. Macrophages were the first
“immune” cells to appear in evolution, are present in virtually all tissues, and far outnumber other
leukocytes (7–9). Despite these anatomical signposts, most immunologists (from the time of Jenner
in the 1700s) have been on a quest for the holy grail of immunology: specificity. One cannot blame
them. Specific vaccines have resulted in the elimination of world disease scourges such as smallpox
and polio.
Meanwhile, macrophages were mainly viewed as “trash disposal units” serving at the bequest of
the T and B cells and hidden “under the sink” (10). One might say an “Adaptive Dictator” was in
charge (9).
Macrophages were also an enigma. They displayed the stupefying polar-opposite abilities to
inhibit proliferation (e.g., kill pathogens) or to promote proliferation (e.g., repair wounds). How
could this be? The kill and repair paradox turned out to be based on the elegantly simple and
fascinating ability of macrophages to metabolize arginine to either nitric oxide (NO) or ornithine,
respectively (11–17). As important as this discovery was, macrophages held another big secret: one
that would fundamentally change our understanding of how immune responses occur.
Macrophages’ unique abilities to kill or repair were found in sterile inflammation, where there
were no pathogens (foreign antigens), and also in mice without T (or B) cells (14, 16). These
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FIGURE 1 | It is useful sometimes to recognize the obvious rather than
look for more complicated explanations in science, or in life.
observations helped overturn the long-held belief that adaptive
responses were necessary to “activate” or “alternatively activate”
macrophages (3, 18–20). The importance and independence of
innate immunity are highlighted by the oft-overlooked fact that
>95% of animals do not have T cells and survive happily in a
sea of pathogens, earthworms being an example (7, 8). How?
Macrophages! They can kill pathogens within hours. Rapid killing
of pathogens is necessary. One bacterium can become the mass of
a human in about 4 days, while a T (or B) cell can only become
about 16 cells in 4 days. Thus, mathematical considerations alone
indicate that clonal proliferation of lymphocytes cannot serve as
the primary host defense; this is the job of macrophages through-
out the animal kingdom (1). Moreover, in higher animals (e.g.,
vertebrates) that do have T cells, kill or repair type macrophages
(or dendritic cells1) necessarily direct T cells to make Th1 or
Th2-type responses, respectively (16, 21–23).
Together, these and other results about macrophages have
caused a fundamental change in our understanding about how
immune systems operate. Macrophages/innate immunity initi-
ates and directs virtually all immune responses, including T and
B cells/adaptive immunity (1, 9). Hence, I specifically renamed
macrophages M1 and M2 to highlight that they, not T cells, are
the core of immune systems (16). Of course, once given innate
direction by macrophages, the different types of Th1 or Th2-type
responses that result can further elevate (or inhibit) M1- or M2-
type macrophage responses (1). The macrophage “revolution” did
not happen overnight, and is continuing. But how macrophages
came out from “under the sink” to occupy the epicenter of
1Macrophages and dendritic cells are both derived from “myeloid” precursor cells.
Whether dendritic cells are a unique cell type or a specialized type of macrophage is
less important than the bigger point that both are innate-type cells that can present
antigens to T cells. So, for convenience, “macrophage” will be used throughout here.
Readers are directed elsewhere for discussions about macrophages and dendritic
cells (21–23).
+
FIGURE 2 | Injection of bovine serum albumin, chemically modified to
be “positively charged,” into a mouse caused it to be retained longer
at the site of injection, and stimulated a stronger T cell mediated
immune response.
immunology is an interesting story that resembles life itself: one of
Direction, Determination, Discouragement, and finally Discovery.
It is about the horses, not zebras, of immunology.
Setting a Course of Study: Cancer and
Immunology
My path to the study of macrophages took awhile. When I entered
graduate school in 1974 at theUniversity of Chicago, immunology
was pretty new. There was only one immunology course avail-
able and few textbooks; so, learning came mainly from reading
journals such as the Journal of Immunology or Journal of Experi-
mental Medicine. I came to believe that the next great immuno-
logic triumph would be more specific vaccines. Having drawn
blood in a hospital, as an undergraduate at Syracuse University,
patients dying of cancer made a profound impression on me. So,
immunology and cancer became my focus: my Direction. At this
time, cancers appeared to be “foreign” like pathogens (24–26) and
viruses were also implicated (27, 28). But, the antigens on cancer
cells were weak; they did not readily elicit specific T (or B) cell
responses (29).
Having decided I wished to study immunology, I joined Robert
Hunter’s lab at the University of Chicago because he was inves-
tigating why some antigens were more immunogenic (elicit an
immune response) than others in hopes of augmenting anti-
cancer and other immune responses (30). While thinking about
a Ph.D. project, I realized that animal bodies, as a whole, are
“negatively charged” (proteins, sugars, cells, etc.). For example,
the electrophoretic separation of most proteins is possible because
they migrate from the anode (-) to the cathode (+) at different
rates. Cells and other molecules must repel, not stick together,
in order to move, to flow. Therefore, I proposed that if a protein
antigen was modified to be “positively charged,” it would “stick”
in the body longer and elicit a stronger immune response as
illustrated in Figure 2. It worked (31).
However, not a lot of people were interested in what made anti-
gens immunogenic in the 1970s (recall theAdaptiveDictatorship),
and my manuscript to the Journal of Immunology was rejected: a
lesson in Discouragement. Along the way, I learned that humor
is a useful way to deal with Discouragement. The south side of
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Chicago wasmore ethnically “diverse” than where I had lived. The
black friends I developed there had the best sense of humor of any
group I have encountered. They used humor artfully to diffuse the
increased societal Discouragement they typically faced compared
to white boys like me.
Investigating how the “charge” of an antigen affects its
immunogenicity may seem far removed from the title of this
paper. However, studying the biochemistry of antigens and how
the immune system handles them provided me with important
tools that would help later in figuring out how immune systems
operate.
With continued excitement that cancer was “foreign” and
with training in what makes antigens immunogenic (particularly
in vivo), I continued in my Determination to boost anti-cancer
responses. I joined Bob North’s lab as a postdoc at the Trudeau
Institute. Back at Chicago, I had become interested in cytolytic T
lymphocytes (CTL) mainly because of Zinkernagel and Doherty’s
work, and because Frank Fitch’s lab next door was measuring
them (32, 33). Bob, Earl Dye, and I found out that we could use
adjuvants (e.g.,C. parvum or LPS) to augment tumor-specific CTL
responses in vivo that handily caused tumor rejection (34, 35).
This was exciting news. The NIH took notice and began clinical
cancer trials trying to boost “killer” lymphocytes (36).
However, a major crack in the “cancer vaccine” armor was
becoming apparent to me. It had been reported that mice defi-
cient in T cells did not have an increased incidence of cancer
(37). It had also been recently proposed that the immune system
could stimulate cancer growth (38). Too, the ongoing NIH clinical
cancer immunotherapy trials themselves needed therapy: they
did not work (39). The T cell-mediated “immunosurveillance”
theory of cancer thus seemed wrong (40): another potential Dis-
couragement. However, I was lucky to be at the Trudeau Institute
because the studies there mostly focused on understanding dis-
eases processes in vivo: an approach I would continue to use. In
addition, macrophage “activation” had been discovered there (18,
41) that openedmy eyes to another cellular element of the immune
system. I also found most interesting the recent observations that
macrophages were required for T cells to be activated (42, 43).
My postdoctoral studies thus added breadth to my immunologic
knowledge that would soon become an advantage: as Pasteur said,
“Chance favors the prepared mind.”
Exploring Macrophages and Solving Their
Enigmatic Kill or Repair Abilities
Because of increasing doubts about the “foreignness” of cancer,
my introduction to macrophages (and moving to Brown Univer-
sity), I adjusted myDirection to focus on the “trash disposal units”
of the immune system. I was also going to learn that collabo-
rating with people whose expertise is very different than one’s
own can be important. I have come to call it “cross-fertilization.”
I teamed up with surgeons Michael Caldwell and Jorge Albina
(and Jeff Shearer) who studied wound metabolism, far differ-
ent from my expertise in immunology. We found macrophages
to be the majority leukocytes in sterile wounds, and that they
produced the growth/repair-promoting molecule, ornithine (a
precursor of polyamines and collagen), that aids in healing (14).
But as I previously mentioned, I had learned from studies at the
Trudeau Institute that macrophage “activation” was necessary to
kill bacterial pathogens (18).
How could one cell perform the polar-opposite activities of
growth inhibition (killing pathogens) and growth promotion
(healing wounds)? This was vexing indeed. Solving this paradox
would eventually lead to the discovery of M1/kill and M2/repair-
type macrophages. Not yet, however, as there was still work to be
done: Determination.
Pursuing wound healing further, we found that macrophages
produced so much ornithine in wounds that they markedly and
specifically depleted the substrate, arginine, in vivo. Could low
arginine concentrations in inflammation be important? As I men-
tioned, I focused on studying immune responses in vivo. How-
ever, dissecting cellular physiology and functions is sometimes
better studied in vitro. Having some skills in biochemistry and
contemporary tissue culture techniques, I was able to test the
hypothesis that low arginine concentrations negatively impact
leukocyte functions. Since macrophages were the predominant
leukocytes in sterile wounds, we harvested some resident rat peri-
toneal macrophages and cultured them in varying concentrations
of arginine. Opposite from our hypothesis, the more arginine we
added to macrophages, the more their functions declined after a
few days.We shelved these experiments, thinking we were dealing
with some undecipherable in vitro artifact. Whereas, this seemed
another potential Discouragement, I got “lucky.”
While perusing the current Journal of Immunology in 1987,
I came upon an article by John Hibbs and colleagues report-
ing that macrophages kill tumor cells using arginine: and only
arginine (12).
Wow (I will use Wow throughout to highlight those rare and
wonderful “realization” moments).
I realized that the reason our experiments of adding arginine
to macrophages decreased (not increased) their functions was
that we were unknowingly adding the “fuel” macrophages use to
kill, and that the mysterious arginine-derived molecule also killed
the macrophages (13). Within months, the arginine-derived killer
molecule would be determined to be NO (44). It was a gas (both
literally and figuratively humor intended), because now there was
an answer to the enigmatic ability of macrophage to kill or repair.
Macrophages have the unique ability to metabolize arginine to
either make a “Stop” signal or a “Go” signal, as illustrated by the
traffic light in Figure 3 [(13), reviewed in Ref. (9, 17)].
Macrophage Kill and Repair Activities in
Wounds and Tumors
The discovery that macrophages could make either a Stop sig-
nal (NO) or a Go signal (ornithine) from arginine was amazing
to me. But, were these polar-opposite activities physiologically
important? We immediately set about determining if and when
macrophages made these Stop or Go molecules in vivo. Recall
that we already knew that macrophages in healing wounds were
making the growth-promoting molecule ornithine. So, we exam-
ined if macrophages were also making NO in wounds. They
did, but only for a few days after wounding (to kill pathogens if
introduced) as shown in Figure 4 (14). I was now convinced that
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these dual arginine-based kill or repair pathways in macrophages
were important in vivo.
In parallel with studying macrophages in wounds, I was con-
tinuing my cancer studies using an intraperitoneal tumor model.
FIGURE 3 |Macrophages have both iNOS and arginase enzymes that
can convert arginine to NO or ornithine, respectively. Products of each
reaction inhibit the opposing reaction, promoting preferential NO or ornithine
production.
FIGURE 4 | (A, C) Following wounding, there is a 1-2 day “burst” of killer NO (measured as Citrulline and NO2) in vivo, followed by (B, D) macrophages metabolizing
arginine to the growth-promoting repair molecule, ornithine (and urea), as healing proceeds. From Ref. (14). Copyright 1990. The American Association.
This site allowed me to look at the cellular and molecular events
going on inside growing tumors, or in tumors being rejected. I
found that macrophages inside growing tumors primarily made
ornithine, just like macrophages in healing wounds. Notably,
macrophages in growing tumors only made ornithine; there was
no initial “burst” of NO as observed following wounding. In
marked contrast, macrophages inside rejecting tumors (preimmu-
nized mice) made a lot of NO (and there was a strong intratumor
CTL response and IFN-γ production) (45). Thus, macrophages
inside growing tumors make a molecule (ornithine) that pro-
motes proliferation, and macrophages inside rejecting tumors
make a molecule (NO) that inhibits proliferation as shown in
Figure 5.
WowThese seminal results in 1990 and 1992 convincedme that
macrophage arginine-based repair or kill responses were not only
important in vivo, but involved with the growth or rejection of
cancer: my original Direction.
Involvement of Macrophage Kill or Repair
Activities in Many Diseases
The findings that macrophages make proliferation-promoting
ornithine during inflammation where cells are growing (healing
wounds or cancer), or make proliferation-inhibiting NO where
cells are being killed caused me to re-double my Determination
to studying these macrophage responses in diseases. My family
and I moved to the University of Minnesota where a great new lab
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FIGURE 5 | (C, D) Macrophages in a growing tumor (naïve) make growth-promoting ornithine (and urea). (A, B) Macrophages in a rejecting tumor (immune) make
killer NO (and citrulline). From Ref. (45). Copyright 1992. The American Association of Immunologists, Inc.
complex had been constructed forMikeCaldwell, Jeff Shearer, and
me. The breadth of immunologic knowledge I had acquired about
macrophages at the Trudeau Institute and collaborations with
people whose expertise was different than mine would continue
to be fruitful.
Along the way, there were some funding and other difficul-
ties: Discouragement. For example, as I did not publish a lot of
papers, funding agencies were perennially “reminding” me of this
(instead of focusing on citation impact). But my Direction and
Determination remained with macrophages.
Damn the torpedoes, full speed ahead! James Farragut,
Civil War, 1864.
Having realized from our earlier studies that when
macrophages make the gas NO it non-specifically kills
everything nearby, I began to wonder if macrophage kill/NO
or repair/ornithine responses were involved in other disease
processes. For example, it had been observed during several
chronic infections that macrophages inhibit specific T (or B)
cell responses through “suppressor” activity (46, 47). Knowing
this, and having the tools to enhance or inhibit NO production,
we were able to show that macrophage “suppressor” activity
(measured in vitro) could largely be attributed to their production
of NO (48). It was also revealed that the presence of red blood
cells blocked the NO-mediated suppressor activity (NO binds
avidly to hemoglobin) (17). But, there are myriad differences
between in vitro leukocyte reactions and how the immune system
operates in vivo, as I have recently discussed (49). I knew that
in rejecting tumors (mentioned earlier, Figure 5) that there
were both specific CTL and macrophages making a lot of NO
(45). This model system allowed me to test if macrophage
NO also inhibited T cells in vivo. We implanted Alzet Pumps
containing N--monomethyl--arginine (iNOS/NO inhibitor)
inside rejecting tumors. Doing so elevated the tumor-specific
CTL response (50). Thus, NO was thus not simply beneficial
against tumors (or pathogens), but also immunoregulatory. If
overproduced, NO could inhibit beneficial immune responses
in vivo [reviewed in Ref. (17)]. In a related connection, we
knew from our earlier studies in wounds that tissue disruption
causes a short “burst” of NO production as shown in Figure 4
(14). It is now clear that this is an evolutionarily old response
that most animals have which serves to “sterilize” the area (in
case pathogens are introduced) – something I have termed the
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“Damage Danger” response (9). It happened upon a surgery
resident at the University of Minnesota who was working with
the noted transplant surgeon David Sutherland. They were trying
to figure out how to improve “islet” transplantation (groups
of insulin-producing β cells from the pancreas) for diabetes
treatment. As in a wound, we found that injecting islets also
caused a short local burst of NO. We were able to show that
inhibiting this rapid NO response increased the efficiency of
cellular transplantation (51). In another study, we found that
β-cell destruction in autoimmune diabetes was also associated
with overproduction of macrophage NO and was regulated by
insulin (52).
The aforementioned results greatly expanded the “universe” of
macrophage NO in vivo from that of a host protective molecule
to an immunoregulatory molecule and a non-specific tissue-
damaging element if overproduced. Subsequent studies have ver-
ified the powerful two-edged sword nature of macrophage NO
(and ornithine) in many infectious and autoimmune diseases (9,
17, 53–57), as we had originally observed in wounds and tumors
(14, 45). Of particular note, overproduction of macrophage NO
appears to be causative in atherosclerosis (58–60). Thus, the bal-
ance between the macrophage killer (NO) and repair (ornithine)
responses now seemed important in both of the two major health
problems of modern man: cancer and atherosclerosis.
Wow Stay tuned; it gets even better.
The Road to M1 and M2 Macrophages
T Cells Determine Immunity: or Do They?
While I was busy studying macrophages, most immunologists
continued to view “immunity” in humans (higher animals) from
a T cell/adaptive immunity perspective. For example, it had been
shown that different strains of mice vary tremendously in their
susceptibility to infectious agents. In particular, C57Bl/6 mice
were much more resistant to Leishmania than were Balb/c mice
(61). The difference in resistance correlated with the ability of
C57Bl/6 mouse T cells to produce a lot of IFN-γ during infection
that activates macrophages to kill the parasite [by now NO was
known to be important in killing intracellular pathogens (62)]. In
contrast, Balb/c T cells made more IL-4 that did not stimulate NO
production, but instead stimulated antibody production, which
was ineffective against the parasite. The IFN-γ dominant T cell
response came to be known as Th1, while the IL-4 dominant
response was called Th2 (2). That hosts mounted very different T
cell responses to Leishmaniawas an exciting development because
it seemed to explain differences in disease susceptibilities.
Butmy immunology experiences had taughtme that correlation
is not causation. Recall which leukocytes are themost abundant in
animals – macrophages – not T cells. The saying that, “If you hear
the sound of hooves, don’t look for zebras” was about to take on
an important new meaning.
Macrophage Responses Vary Between
Individuals Independent of T Cells
Knowing there were major differences in the T cell responses
of different mouse strains to Leishmania, I wondered if the
macrophage killer and repair responses I was studying also varied.
We harvested resident tissue macrophages from C57Bl/6 and
Balb/c mice (and a few other strains), and compared their abilities
to make the killer molecule NO or the repair molecule ornithine.
Note: unlike most, I used resident macrophages, not “elicited”
macrophages. Though the cell yield was much lower (more mice
needed), it allowed me to look at “resting” macrophages. Resident
C57Bl/6 macrophages were much easier to stimulate to make NO
(with IFN-γ or LPS) than were Balb/c macrophages. Further-
more, LPS stimulated NO production by C57Bl/6 macrophages,
but instead caused increased ornithine production by Balb/c
macrophages (16). Thus, using the same stimulus C57Bl/6 mouse
macrophages could produce a growth-inhibiting molecule while
Balb/c made a growth-promoting molecule. This was very inter-
esting. Also, because the stimuli used were not specific to
Leishmania the results suggested that differences in macrophage
responses between mouse strains were general phenomena. Hav-
ing an amino acid analyzer available (because of our interest
in metabolism), importantly made direct measurement of the
arginine-derived kill (NO) and repair (ornithine) molecules pos-
sible: a point I will discuss later. We made our own serum-free
culture media for these experiments because it was known that
serum contains high levels of TGF-β (mainly from lysed platelets)
that strongly inhibits macrophage NO production (17). Serum-
freemedia also allowedus to show thatmacrophagesmakeTGF-β,
and when they are stimulated to make NO, TGF-β production
goes down, as shown in Figure 6. Subsequent studies have con-
firmed that TGF-β is a key cytokine that regulates the balance
between macrophage NO and ornithine production (1, 16, 17,
63–66).
The differences observed in the responsiveness of C57Bl/6 and
Balb/c macrophages to LPS or IFN-γ suggested that resistance to
Leishmaniamight involve macrophages. To rule out the influence
of T (or B) cells, I compared the ability of C57Bl/6 or Balb/c Nude
or SCID macrophages to make NO or ornithine. The results were
breathtaking. C57Bl/6 Nude or SCID macrophages made a lot of
NO while Balb/c Nude or SCID macrophages did not, just like
their normal counterparts (16).
MajorWow
The propensity of macrophages to make killer or repair
responses was independent of T (or B) cells. Could this also mean
that differences in macrophages between individuals (not T cells)
determine susceptibility to Leishmania or other diseases?
The Discovery and the Importance of M1 and M2
Macrophages
As part of investigating macrophage kill or repair responses in
different mouse strains, I also wondered whether the propen-
sity of C57Bl/6 or Balb/c T cells to make IFN-γ (Th1) or IL-
4 (Th2), respectively, was only true in Leishmania infection.
It was not. When I stimulated C57Bl/6 or Balb/c spleen cells
with Con A (polyclonal stimuli), they made more IFN-γ or IL-
4, respectively. Thus, C57Bl/6 and Balb/c mice had a general
propensity to make Th1- or Th2-type cytokines. But why? To
answer this question, I designed an experiment that perhaps only
an immunologist/immunogeneticist could enjoy. We harvested
C57Bl/6Balb/c F1 spleen cells and depleted the macrophages
and red blood cells. Then, we mixed the F1 lymphocytes with
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FIGURE 6 | Dominant NO production by C57B/6 macrophages compared to Balb/c macrophages. Also, NO production is inversely proportional to
macrophage TGF-β production. From Ref. (16). Copyright 2000. The American Association of Immunologists, Inc.
FIGURE 7 |Macrophages from C57Bl/6 mice make M1-dominant (NO)
responses while Balb/c are M2-dominant (ornithine). M1- or
M2-dominant responses stimulate Th1- or Th2-type responses that can
further amplify cellular/CTL and M1, or antibody-type and M2 responses.
From Ref. (1) with permission from S. Karger AG, Basel.
macrophages from SCIDC57Bl/6 or SCID Balb/c mice and added
Con A. C57Bl/6 SCID macrophages caused the T cells to make a
Th1-type response (IFN-γ) and Balb/c SCIDmacrophages caused
the same type of T cells to make a Th2-type response (TGF-β)
(16). Note: these experiments were possible because F1 T cells do
not recognize either parent as foreign. Differences in macrophage
responses alone could explain the ability of different mice to
mount Th1- or Th2-type responses and in turn their susceptibility
to diseases. Macrophages direct T cells as illustrated in Figure 7.
DiscoveryWow
Because of their polar-opposite kill and repair activities, the
independence of these responses fromT cells, and that these types
of responses stimulated Th1- or Th2-type responses, I renamed
macrophages M1 and M2 to highlight the importance of innate
immunity over adaptive immunity (16). M1/inhibit and M2/heal
responses and their impacts on inflammation and immunity
are illustrated in Figure 8. The long-held belief that “zebras”
(T cells) were necessary to “activate” or “alternatively activate”
macrophages was incorrect and even backward (3–6, 19, 20). The
adaptive dictator had been overthrown. The horses/macrophages
were the center of the immune “solar” system. Anatomy was
proven correct after all.
M1 and M2 Macrophage Responses
Defined
Causative Functions and Molecules that Affect
Health
As described, M1 and M2 macrophage responses were originally
defined in vivo by the preferential production of the causative
functional molecules NO or ornithine which inhibit or promote
proliferation. Since then M1 or M2 macrophages responses have
been shown to occur in concert with certain other molecules that
can aid in characterization. As shown in Figure 9, M1 responses
are linked with IL-12 and IL-8/CCL production, and cell surface
expression of CD 80 or 86 that attract or killer cells like neu-
trophils and/or stimulate Th1 responses such as CTL and further
M1-type activation. M2 responses are associated with TGF-β,
and growth factor production (e.g., VEGF or EGF), cell surface
expression of CD163 or 206, and the propensity to stimulate Th2
responses such as antibody production and further amplification
of M2-type responses, as illustrated in Figure 7. Macrophages
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FIGURE 8 |Macrophages initiate and direct other immune responses.
For example, M1-type responses (e.g., through IL-12 and antigen presentation)
direct T cells to become cytolytic T cells and produce IFN-γ that further elevates
M1 activity. In contrast, M2-type macrophages cause T cells to produce
molecules like IL-4 and TGF-β that cause B cells to produce antibody and
elevate M2 responses. From Ref. (1) with permission from S. Karger AG, Basel.
FIGURE 9 | Cytokines and other molecules associated with M1/inhibit
or M2/heal-type responses. Certain products (middle) have been
associated with both M1 and M2-type responses and can be thought of as
general “inflammatory” cytokines or factors. From Ref. (1) with permission
from S. Karger AG, Basel.
also make TNF-α, IL-6, IL-1, IL-10, NADPH oxidases, and met-
alloproteinases. However, these molecules are produced by many
macrophage populations and are not as clearly diagnostic of M1
or M2-type responses as NO or ornithine or the other molecules
listed in Figure 9.
Other Markers of Macrophages
As mentioned above, in addition to molecules that are closely
linked to M1 and M2-type macrophage responses, macrophages
produce a variety of other what can be called “inflammatory”
molecules. However, as mentioned earlier with T cells and Leish-
mania resistance, correlation is not causation. In this regard,
some refer to M1 or M2-type responses as “pro-inflammatory”
or “anti-inflammatory.” But, this practice is misleading. For
example, M2-type responses dominate in wounds as shown in
Figure 4. As anyone knows awound is hardly “anti-inflammatory.”
Wherever macrophages accumulate, there is inflammation. So,
molecules like IL-1 or IL-6 are more diagnostic of the presence
of macrophages rather than of M1 or M2-type responses. In turn,
the use of these inflammation-type markers by some laboratories
has lead to classifying macrophage populations as M1 or M2-type
that are not. In a related vein, techniques like transcriptomics and
FACS (67–69) are creating ever-enlarging lists of other “markers”
being used in analysis of macrophage populations, and individual
laboratories often use their own particular markers. Not surpris-
ingly then, these variations in the “metrics” used has created
confusion in trying to classifymacrophage populations. For exam-
ple, various different names have been proposed for macrophages
such as: M2 a, b, c; type II; or regulatory macrophages (69–
71). But, such “subsets” do not have distinct functions associated
with them in vivo like M1/kill or M2/repair. To try and address
this confusion, a new “nomenclature” was recently suggested to
classify macrophages (72). However, the nomenclature suggested
is also not based on functions, but mainly on what cytokine or
factor was added to macrophages in vitro. In this connection, the
various combinations of different cytokines, agonists, or markers
that can be employed in stimulating or analyzingmacrophages are
very high. But the number of macrophage functions is small.
Specifically, macrophages have four core functions called SHIP
[sample, heal (M2), inhibit (M1), and present (antigen)] as shown
in Figure 10. Therefore, to best understand macrophage pop-
ulations it is important to stay focused on analyzing them by
functions, such as SHIP, that are known to affect health as recently
discussed (1, 49).
Heterogeneity and Plasticity are not Macrophage
Functions
Infections, cancer, or other inflammatory conditions are ever
evolving as disease protection or progression occurs. This fact
and that macrophages have the unique ability to drastically
change their physiology to protect hosts necessarily means that
macrophage populations are heterogeneous. Plasticity, a term I
coined in 2001 (17), was later popularized by my now deceased
friend, Bob Stout, and his wife Jill Suttles (73). Plasticity is a useful
word to describe the unique ability of macrophages to change
their functions. Beyond this, some have posited that macrophages
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FIGURE 10 |Macrophages have four basic SHIP functions [sample,
heal, inhibit and present (antigen)] that allow them to recognize
pathogens or injury, and respond directly (or indirectly by presenting
antigens) to engender responses that provide optimal host protection.
From Ref. (1) with permission from S. Karger AG, Basel.
are like a “color wheel” (74). But, it is important to note that
heterogeneity, plasticity, or color wheels are not functions that
affect health. For example, as we saw, M2-type macrophages
inside tumors promote tumor growth while M1-type inhibits
tumor growth as illustrated in Figure 5 (45). These findings have
since been verified in many human cancers (75–78). Therefore, if
one has cancer, one would wish to decrease intratumor M2-type
and increase M1-type macrophages. Heterogeneity, plasticity, or
color wheels will not stop cancer. So, though such terms are useful
in describing the fungibility of macrophage populations, again,
advancing health will only come from knowing what macrophage
functions are by measuring them, so they can be modulated as
needed (49).
Parallel Elements of the “4Ds” in Scientific
Investigations and Life
As I said at the outset, events in biomedical research can resemble
life itself: there is Direction, Determination, Discouragement, and
Discovery.
I feel most fortunate in having an upbringing that allowed me
to become a scientist. I have met many people along the way with
towering intelligence, but who did not have such an advantage and
who work at difficult manual labor jobs. I was also fortunate in
being influenced early in my Direction by seeing the devastation
that cancer can bring, and in picking immunology to study cancer.
Regarding Determination, many people work hard and I am not
unique. But in science, one should not “fall in love” with one’s
ideas. As described here,Wow-type moments often come through
serendipity: when one must trust the results and abandon existing
hypotheses. Recognizing that cancer was not overtly “foreign”,
and focusing on macrophages/innate immunity was one of those
moments for me. One cannot know everything about an immense
field such as immunology. However, I think cultivating a breadth
of knowledge helped prepare me for times when, “Chance favors
the prepared mind”, such as elucidating the arginine-based dual
M1/inhibit or M2/heal functions of macrophages (16, 17). As I
mentioned earlier, my belief in the importance of macrophages
was bolstered by the findings that they were necessary stimula-
tors of T cells (21, 22). Also, toll receptors were identified on
macrophages in the 1990s (79–81) that provided additional sup-
port for my concept that macrophage responses are independent
of T cells, and also initiate immune responses. As a sidebar here, I
worked with Ralph Steinman some when I was a postdoc at the
Trudeau Institute in the early 1980s and enjoyed his company.
He is credited with discovering dendritic cells (21). It may well
be from me having a lack of folds in my cerebrum, but I have
always found it simpler to consider dendritic cells as a subset of
macrophages (17). So, if you are dendritic cell “fan,” you could
substitute those words for macrophages in some places in this
treatise. But, it does not change the larger point that M1/M2-
typemacrophages have the unique ability to display polar opposite
kill or repair responses and that innate immunity directs adap-
tive immunity. I will leave the macrophage versus dendritic cell
discussion to others (22, 23).
As I said earlier, there was Discouragement along the way. As
anyone in biomedical research knows, funding one’s work can be
difficult and frustrating. In my own case, I knew deep down I
had found something beautiful about the immune system in the
Discovery of M1/inhibit and M2/heal-type macrophages in 2000.
But dogma can be slow to change, and I did not get an important
NIH grant renewed. Having had my own lab for many years, I
did not wish to work for someone else, and I left the University
of Minnesota to do other things for a while. One very satisfying
thing I did was coach my sons and daughter’s basketball teams. I
feel sports teach important life lessons, such as fair play, and being
gracious in victory or defeat.
In the mid 2000s, my M1/M2 Discovery started to be appreci-
ated. Of course, medical research is very competitive; so, it was not
surprising that some tried to rewrite history about macrophage
subsets (69, 70). In particular, it is “curious” that some reviews
about M1 or M2-type tumor-associated macrophages (82, 83)
somehow overlook the seminal studies that elucidated the M1
growth-inhibiting and M2 growth-promoting macrophages in
tumors and wounds [e.g., Figures 4 and 5; (14, 45)]. Like I
mentioned about sports and fair play, it is appropriate to try
and acknowledge other’s studies. In this connection, Zouhair
Atassi recognized that I was the origin of the M1/M2macrophage
concept, and asked me to write a review for Critical Reviews in
Immunology in 2012 that I entitled, “M1and M2 Macrophages:
Oracles of Health and Disease” (9).
The M1/M2 concept has fundamentally changed our under-
standing of what “immunity” is by showing the biochemical bases
for the unique abilities of macrophages to kill or repair, and
that macrophages/innate immunity initiate and direct immune
responses throughout the animal kingdom, including adaptive
immunity in humans (1, 7, 8, 16). M1/M2 has not only stood the
test of time, but thousands of publications indicate that interest in
macrophages/innate immunity and clinical applications are ever
increasing. I apologize for not mentioning many good results
about M1 and M2 macrophages here, but readers should be able
to track down studies of interest from the reference list. I am
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FIGURE 11 |M1/inhibit or M2/heal-dominant macrophage responses (or mixtures) can each be beneficial or detrimental depending on the disease
circumstance. For example, M1/Th1-dominant responses are required to fight many infections (left). But, M1/Th1 responses are also causative of destructive
inflammatory conditions in the brain and in atherosclerosis (right).
particularly gratified that there is great potential for the success-
ful immunotherapy of cancer by modulating M2 into M1-type
macrophages (76, 84): my originalDirection. Indeed, Sciencemag-
azine referred to 2013 as the year of immunotherapy. Some exam-
ples of the myriad diseases where the powerful two-edged sword
nature of M1 or M2-dominant macrophage responses can be
beneficial or detrimental are illustrated inFigure 11.Macrophages
are indeed the oracles of health or disease.
I hope you got a “charge” (humor frommy Ph.D. earlier) out of
“Anatomy of a Discovery” and experience your ownWows.
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